FDA Renews Pharmacy Compounding Advisory Committee for Two More Years
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice extends the FDA’s Pharmacy Compounding Advisory Committee through April 25, 2028. The committee advises FDA on drug compounding issues under sections 503A and 503B of the Food, Drug, and Cosmetic Act, so the main impact is continued expert input for compounding pharmacies, manufacturers, physicians, and patient groups. There is no change to the committee’s duties or the underlying FDA rules.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA renews the Pharmacy Compounding Advisory Committee for another two years.
- The committee remains in place until April 25, 2028.
- No change is made to the committee’s name, duties, or FDA regulations.
Obligations
What this law requires
FDA must keep the Pharmacy Compounding Advisory Committee charter in effect through April 25, 2028, by renewing the committee for an additional two years beyond the prior expiration date.
FDA must renew the Pharmacy Compounding Advisory Committee’s charter so the committee remains in effect until April 25, 2028.
FDA must keep the Pharmacy Compounding Advisory Committee renewed and in effect through April 25, 2028.
The Commissioner or designee must continue to maintain a Pharmacy Compounding Advisory Committee with at least 10 voting members, including a Chair, selected from qualified experts in pharmaceutical compounding, pharmaceutical manufacturing, pharmacy, medicine, and related specialties.
The Commissioner or designee must appoint and maintain a Committee with at least 10 voting members, including a Chair, selected from individuals knowledgeable in pharmaceutical compounding, pharmaceutical manufacturing, pharmacy, medicine, and related specialties.